The Gross Law Firm
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of OCGN, ATHA and DIDI
NEW YORK, NY / ACCESSWIRE / July 15, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.
Ocugen, Inc. (NASDAQ:OCGN)
Investors Affected : February 2, 2021 - June 10, 2021
A class action has commenced on behalf of certain shareholders in Ocugen, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the information submitted to the U.S. Food and Drug Administration ("FDA") was insufficient to support an Emergency Use Authorization ("EUA"), (ii) Ocugen would not file an EUA with the FDA, (iii) as a result of the foregoing, the Company's financial statements, as well as Defendants' statements about Ocugen's business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
Shareholders may find more information at https://securitiesclasslaw.com/securities/ocugen-inc-loss-submission-form/?id=17686&from=1
Athira Pharma, Inc. (NASDAQ:ATHA)
This lawsuit is on behalf of investors who purchased Athira Pharma, Inc. (NASDAQ: ATHA) between September 18, 2020 and June 17, 2021 and/or purchased common stock in or traceable to the Company's registration statement issued in connection with the Company's September 2020 initial public offering priced at $17.00 per share.
A class action has commenced on behalf of certain shareholders in Athira Pharma, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the research conducted by Defendant Kawas, which formed the foundation for Athira's product candidates and intellectual property, was tainted by Kawas' scientific misconduct, including the manipulation of key data through the altering of Western blot images; and (2) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and omitted material facts necessary in order to make the statements made not misleading.
Shareholders may find more information at https://securitiesclasslaw.com/securities/athira-pharma-inc-loss-submission-form/?id=17686&from=1
Didi Global Inc. F/K/A Xiaoju Kuaizhi Inc. (NYSE:DIDI)
This lawsuit is on behalf of persons and entities that purchased or otherwise acquired DiDi: (a) American Depositary Shares pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's June 2021 initial public offering; and/or (b) securities between June 30, 2021 and July 2, 2021, inclusive.
A class action has commenced on behalf of certain shareholders in Didi Global Inc F/K/A Xiaoju Kuaizhi Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) DiDi's apps did not comply with applicable laws and regulations governing privacy protection and the collection of personal information; (2) as a result, the Company was reasonably likely to incur scrutiny from the Cyberspace Administration of China; (3) the CAC had already warned DiDi to delay its IPO to conduct a self-examination of its network security; (4) as a result of the foregoing, DiDi's apps were reasonably likely to be taken down from app stores in China, which would have an adverse effect on its financial results and operations; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
Shareholders may find more information at https://securitiesclasslaw.com/securities/didi-global-inc-f-k-a-xiaoju-kuaizhi-inc-loss-submission-form/?id=17686&from=1To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Phone: (212) 537-9430
Fax: (833) 862-7770
SOURCE: The Gross Law Firm
View source version on accesswire.com:
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
iZafe Group14.10.2021 20:31:56 CEST | Press release
The Price for Dosell Consumer is Communicated
iZafe Group14.10.2021 14:28:43 CEST | Press release
Launch of Dosell Consumer in Italy
TECO 2030 ASA14.10.2021 09:58:48 CEST | Press release
TECO 2030 Signs Supply Frame Agreement with Chemgas Shipping
iZafe Group14.10.2021 09:41:43 CEST | Press release
Launch of Dosell Consumer in Italy
NanoViricides, Inc. 13.10.2021 12:46:57 CEST | Press release
NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug Program Rapidly Moving Towards Clinical Stage
iZafe Group13.10.2021 09:21:42 CEST | Press release
Completion of Patents to International Markets
Physitrack13.10.2021 08:21:38 CEST | Press release
Invitation to Physitrack PLC Q3 Interim Report 2020/2021 Webcast Conference
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom